ERBB2 and melanoma: To investigate the impact of the treatments on key signaling pathways involved in melanoma progression, we evaluated the expression and activation status of ERBB2, BRAF, PI3K, AKT1, and mTOR by immunofluorescence analysis (Figure 4 and Figure 5).